• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Alpha Tau Medical (DRTS) Is Down 7.7% After Reporting 100% Response In Alpha DaRT Combo Study

    Simply Wall St·07/26/2026 08:23:55
    Listen to the news
    • In July 2026, Alpha Tau Medical reported clinical data showing a 100% objective response rate and encouraging survival outcomes from its Alpha DaRT plus pembrolizumab study in elderly patients with advanced head and neck squamous cell carcinoma, with minimal Alpha DaRT-related toxicity and results presented at a major international cancer conference.
    • The trial met its pre-specified success threshold under a Simon two-stage adaptive design, allowing early completion of enrollment after more than six responders, underscoring how a small single-center study can still yield clinically meaningful signals in a difficult-to-treat population.
    • We’ll now examine how the strong objective response rate in combination with pembrolizumab could shape Alpha Tau Medical’s broader investment narrative.

    AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

    What Is Alpha Tau Medical's Investment Narrative?

    For Alpha Tau, being a shareholder really comes down to believing that Alpha DaRT can convert today’s early clinical signals into tomorrow’s commercial products across several hard-to-treat cancers, before the company’s cash runway and dilution risk catch up with it. The new head and neck data, with a 100% objective response rate alongside pembrolizumab, clearly strengthens the near-term catalyst set by adding another potential combo story to the ongoing pivotal cSCC program, GBM REGAIN trial and growing pancreatic portfolio. That said, the trial’s tiny, single-center design and the absence of revenue mean the market may treat this as hypothesis-generating rather than thesis-changing, at least until larger datasets or regulatory milestones follow, which leaves execution risk, valuation and funding needs as the central questions.

    However, investors also need to consider how ongoing losses and dilution risk could influence outcomes. According our valuation report, there's an indication that Alpha Tau Medical's share price might be on the expensive side.

    Exploring Other Perspectives

    DRTS 1-Year Stock Price Chart
    DRTS 1-Year Stock Price Chart
    The Simply Wall St Community’s single fair value estimate sits at US$14.20, reflecting one clear-cut viewpoint. By contrast, recent trial successes, cash burn and dilution risk give you plenty of reasons to weigh alternative scenarios for Alpha Tau’s longer term performance.

    Explore another fair value estimate on Alpha Tau Medical - why the stock might be worth as much as 14% more than the current price!

    Reach Your Own Conclusion

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Searching For A Fresh Perspective?

    These stocks are moving-our analysis flagged them today. Act fast before the price catches up:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.